Valuation: GlaxoSmithKline Pakistan Limited

Market Cap 110B 397M 340M 318M 291M 547M 38B 554M 3.76B 1.47B 19.09B 1.49B 1.46B 63.15B P/E 2026 *
10x
P/E 2027 * 8.57x
Enterprise Value 110B 397M 340M 318M 291M 547M 38B 554M 3.76B 1.47B 19.09B 1.49B 1.46B 63.15B EV / Sales 2026 *
1.6x
EV / Sales 2027 * 1.48x
Free-Float
-
Yield 2026 *
5.31%
Yield 2027 * 6.02%
03/08 GlaxoSmithKline Pakistan Limited Appoints Umair Majeed as Interim/Acting Chief Financial Officer, Effective from July 30, 2026 CI
03/08 GlaxoSmithKline Pakistan Limited Announces Appointment of Hasham Ali Baber as Non-Executive Director, Effective July 30, 2026 CI
08/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Chief Financial Officer, Effective June 30, 2026 CI
08/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Executive Director of the Board of Directors, Effective June 30, 2026 CI
01/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Ana Paula De Freitas Passos as Non-Executive Director, Effective May 31, 2026 CI
30/04 GlaxoSmithkline Pakistan Limited Approves Final Cash Dividend for the Year Ended 31 December, 2025 CI
30/04 GlaxoSmithkline Pakistan Limited Approves Board Elections, Effective May 25, 2026 CI
27/04 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
09/04 GlaxoSmithKline Pakistan Limited Proposes Final Cash Dividend for the Financial Year Ended 31 December 2025 CI
07/04 GlaxoSmithKline Pakistan Limited Announces Board Changes CI
31/03 GlaxoSmithKline Pakistan Limited Announces Resignation of Lai Kuen Goh as Chairperson and Non-Executive Director, with Effect from March 31, 2026 CI
26/03 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
25/10/25 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
1 day+1.59%
1 week+0.37%
Current month+0.09%
1 month-0.92%
3 months+3.18%
6 months-12.42%
Current year-11.24%
1 week 339.6
Extreme 339.6
349.99
1 month 337.5
Extreme 337.5
361.75
Current year 293.09
Extreme 293.09
459.27
1 year 293.09
Extreme 293.09
459.94
3 years 68
Extreme 68
481
5 years 68
Extreme 68
481
10 years 68
Extreme 68
481
Manager TitleAgeSince
Chief Executive Officer - 01/03/2020
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 07/05/2011
Director/Board Member - 05/12/2018
Director/Board Member 72 02/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.59%+0.37%-18.37%+379.77% 397M
+0.88%+6.38%+76.40%+126.75% 1,119B
+1.07%+3.80%+50.73%+62.78% 651B
+1.20%+6.21%+25.81%+78.74% 468B
+1.02%+5.77%+43.63%+48.43% 374B
+0.85%+4.07%+24.97%+40.58% 302B
+1.26%+6.81%+2.27%+14.41% 259B
+1.88%+5.81%+49.57%+70.53% 238B
+1.59%+2.09%-17.33%-52.62% 208B
+1.87%+5.61%+27.32%+91.38% 181B
Average +1.32%+4.50%+26.50%+86.07% 380.03B
Weighted average by Cap. +1.14%+5.09%+44.25%+72.68%

Financials

2026 *2027 *
Net sales 68.81B 248M 213M 199M 182M 342M 23.74B 346M 2.35B 916M 11.92B 932M 911M 39.44B 74.58B 269M 230M 215M 197M 370M 25.72B 375M 2.55B 993M 12.92B 1.01B 988M 42.74B
Net income 10.49B 37.82M 32.4M 30.31M 27.75M 52.07M 3.62B 52.76M 358M 140M 1.82B 142M 139M 6.01B 12.42B 44.78M 38.36M 35.89M 32.85M 61.66M 4.28B 62.47M 424M 165M 2.15B 168M 164M 7.12B
Net Debt - -
Logo GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology, and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty, and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate, and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
Employees
1,606
Date Price Change Volume
21/08/26 PKR 345.96 +1.59% 140,389
20/08/26 PKR 340.54 +0.03% 554,697
19/08/26 PKR 340.44 -0.81% 194,033
18/08/26 PKR 343.21 -0.58% 159,489
17/08/26 PKR 345.21 +0.15% 99,357
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
345.96PKR
Average target price
510.00PKR
Spread / Average Target
+47.42%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLAXO Stock